Biocartis receives €1.9 M subsidy for the development of new cancer tests

Please login or
register
25.02.2013
Biocartis will use this IWT-subsidy (from the Flemish government) to develop new diagnostic cancer tests that will facilitate more targeted treatment and improve survival rates for patients.

Biocartis is a molecular diagnostics company that develops clinically relevant tests and innovative, easy-to-use platforms to be employed, amongst other indications, in the fight against cancer. With this grant, the Belgian Agency for Innovation by Science and Technology (IWT) has affirmed its support for the innovative character of Biocartis.

During the two-year project a number of new cancer tests will be developed to be used on the fully automated Biocartis systems. The tests will detect known, validated oncogenes (cancer-causing mutations in the genome) and allow for more targeted treatment of certain cancers. The project will focus on skin, colon and lung cancer. Biocartis will also develop tests that permit the simultaneous detection of dozens of parameters for use with its recently launched multiplex detection platform aimed at the research market.

"Oncology is our company’s primary focus for the development of diagnostic tests. This grant will speed up the development of a broad range of clinically relevant tests that will help make cancer treatment more efficient and personalized as well as improve survival rates for patients,” says Erwin Sablon, Head of Applied Assay Development.

Biocartis was founded in 2007. The company is based at the EPFL's Innovation Square in Lausanne, Switzerland; it has a fully owned Belgian subsidiary in Mechelen and a Dutch subsidiary at the High Tech Campus in Eindhoven. Biocartis is a rapidly growing company; to date Biocartis staff includes over 150 people. The company has raised in total close to EUR 150 million in equity.

0Comments

rss